Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carc...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 39; no. 9; p. 1020
Main Authors:	McDermott, David F, Lee, Jae-Lyun, Bjarnason, Georg A, Larkin, James M G, Gafanov, Rustem A, Kochenderfer, Mark D, Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S, Alonso-Gordoa, Teresa, Cho, Daniel C, Geertsen, Poul F, Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, Atkins, Michael B
Format:	Journal Article
Language:	English
Published:	United States 20.03.2021
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Female Follow-Up Studies Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Male Middle Aged Non-Randomized Controlled Trials as Topic Prognosis Survival Rate
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!